Biomarker Strategies, LLC
PathMAP Immunotherapy test, an ex vivo diagnostic that predicts NSCLC patient response to immune checkpoint inhibitors using the SnapPath Cancer Diagnostics System to process and functionally interrog
- Sector
- Medtech
- Headquarters
- Derwood, MD
- Founded
- 2006
- Latest Form D
- $525K, Sep 2016
- Total capital
- $8.9M
- Federal grants
- $5.3M
- 6 awards · 2015–2018
- Rank in peer group#28 of 112
- Private capital raised
- $3.6M
- 7 Form D · last Sep 2016
- 122 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$994K
- Federal grantHealth and Human S · Phase I · Development of a companion diagnostic to predict response to cetuximab in patients with head and neck squamous cell carcinoma$299K
- Federal grantHealth and Human S · Phase II · PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$2M
- Private capital raisedForm D · SEC · 6th filing$525K
- Federal grantHealth and Human S · Phase II · PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.$300K
- Private capital raisedForm D · SEC · 5th filing$125K
- Private capital raisedForm D · SEC · 4th filing$1.1M
- Private capital raisedForm D · SEC · 3rd filing$1.1M
- Private capital raisedForm D · SEC · 2nd filing$273K
- Private capital raisedForm D · SEC · 1st filing$439K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
3 records have no date or no amount, so they aren’t placed on the timeline.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#28 · top 25%
- Linked publications#16 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Christina WyskielExecutive Officer, DirectorNamed in SEC Form D filings
- Christine WyskielDirectorNamed in SEC Form D filings
- Cy CabradillaExecutive OfficerNamed in SEC Form D filings
- Douglas ClarkDirectorNamed in SEC Form D filings
- Glenn MillerDirectorNamed in SEC Form D filings
- Jack DavisDirectorNamed in SEC Form D filings
Show all 15 people
- Jason RubinDirectorNamed in SEC Form D filings
- Jerry ParrottExecutive Officer, DirectorNamed in SEC Form D filings
- Joseph KleinDirectorNamed in SEC Form D filings
- Karen OlsonExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Katarzyna KusmierzDirectorNamed in SEC Form D filings
- Mark VellecaDirectorNamed in SEC Form D filings
- Paul BeresfordDirectorNamed in SEC Form D filings
- Sam BroderDirectorNamed in SEC Form D filings
- Scott AlloccoExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingMethods To Improve Patient Response To Immune Checkpoint Inhibitors And Functional Tests To Predict ResponseUSPTOApplication 17761077
- PendingMethods To Increase The Sensitivity And Reversing The Resistance To DrugsUSPTOApplication 17761461
- PendingMethods And Devices For Cellular AnalysisUSPTOApplication 14831789
Show all 9 patent records
- Methods To Improve Patient Response To Immune Checkpoint Inhibitors And Functional Tests To Predict ResponseNov 3, 2022 · Application 17761077Pending
- Methods To Increase The Sensitivity And Reversing The Resistance To DrugsOct 27, 2022 · Application 17761461Pending
- Methods And Devices For Cellular AnalysisDec 10, 2015 · Application 14831789Pending
- Methods To Improve Patient Response To Immune Checkpoint Inhibitors And Functional Tests To Predict ResponseApplication 62902302Pending
- Methods To Increase The Sensitivity And Reverse The Resistance To DrugsApplication 62902330Pending
- Compositons And Methods For Prediction Of Drug Sensitivity, Resistance, And Disease ProgressionApplication PCTUS2011032935Pending
- Improved Methods And Devices For Cellular AnalysisApplication PCTUS2008012148Pending
- Methods To Increase The Sensitivity And Reversing The Resistance To DrugsApplication PCTUS2020051209Pending
- Methods To Improve Patient Response To Immune Checkpoint Inhibitors And Functional Tests To Predict ResponseApplication PCTUS2020051197Pending
Recent research by its founders
- List of contributors20250 cites
- Meprin A20250 cites
- Meprin B20250 cites
Related companies, and why
- Procure Holdings, LLCSimilar federal contract value in Medtech · null in contracts
- MECHANOBIOLOGIX, LLCSimilar federal contract value in Medtech · null in contracts
- INNOVAPREP, LLCSimilar federal contract value in Medtech · null in contracts
- PHINOMICS INCSimilar federal contract value in Medtech · null in contracts
- Exact Imaging Inc.Similar federal contract value in Medtech · null in contracts
- QRS DIAGNOSTICSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .